Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mo | NKGen Biotech, Inc. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | 3 | SEC Filings | ||
13.03. | NKGen Biotech, Inc.: NKGen Biotech To Present on Potential of Troculeucel for the Treatment of Neurodegenerative Diseases at the 13th Annual Alzheimer's & Parkinson's Drug Development Summit | 1 | GlobeNewswire (USA) | ||
11.03. | NKGen Biotech, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
04.03. | NKGen Biotech wechselt nach Nasdaq-Delisting zum OTC-Markt | 6 | Investing.com Deutsch | ||
04.03. | NKGen Biotech shifts to OTC Markets after Nasdaq delisting | 5 | Investing.com | ||
04.03. | NKGen Biotech, Inc. to Transition from the Nasdaq Global Market to OTC Markets; Reverse Stock Split will not be Implemented | 334 | GlobeNewswire (Europe) | Trading commencing on the OTC Markets on March 5, 2025.Trading expected to continue under ticker symbol "NKGN" for common stock and "NKGNW" for warrants.NKGen Biotech, Inc. ("NKGen" or the "Company")... ► Artikel lesen | |
04.03. | NKGen Biotech, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
NKGEN BIOTECH Aktie jetzt für 0€ handeln | |||||
25.02. | NKGen Biotech, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
21.02. | NKGen Biotech Announces Administration of First Dose of Troculeucel to Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program | 130 | GlobeNewswire (Europe) | SANTA ANA, Calif., Feb. 21, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization... ► Artikel lesen | |
19.02. | NKGen Biotech: NKGen Appoints Dr. Anita Fletcher as National Principal Investigator for Phase 2a Troculeucel Trial Evaluating Moderate Alzheimer's Disease with AdventHealth Orlando as First East Coast Site | 3 | GlobeNewswire (USA) | ||
02.01. | NKGen Biotech, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
12.12.24 | NKGen Biotech, Inc. - 8-K, Current Report | - | SEC Filings | ||
04.12.24 | NKGen Biotech, Inc. - 8-K, Current Report | - | SEC Filings | ||
02.12.24 | NKGen Biotech, Inc.: NKGen Biotech Selected as Stalking Horse Bidder for NKMax | 1 | GlobeNewswire (USA) | ||
26.11.24 | NKGen Biotech faces Nasdaq compliance issue | 2 | Investing.com | ||
26.11.24 | NKGen Biotech, Inc.: NKGen Biotech Receives Notifications From Nasdaq Related to Delayed Quarterly Report and Decision of the Nasdaq Hearings Panel | 146 | GlobeNewswire (Europe) | SANTA ANA, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) ("NKGen" or the "Company"), today announced it received a notice (the "Notice") on November 20, 2024 from the... ► Artikel lesen | |
26.11.24 | NKGen Biotech, Inc. - 8-K, Current Report | - | SEC Filings | ||
15.11.24 | NKGen Biotech, Inc. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | - | SEC Filings | ||
12.11.24 | NKGen Biotech, Inc. - 8-K, Current Report | - | SEC Filings | ||
29.10.24 | NKGen Flat on Presentation of Alzheimer's Treatment | 2 | Baystreet.ca |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
PALATIN TECHNOLOGIES | 0,477 | -11,83 % | Palatin Techs Aktie: Positive Signale setzen! | Biotechnologieunternehmen erreicht wichtigen regulatorischen Durchbruch mit oralem Wirkstoff gegen genetisch bedingte Fettleibigkeit und verzeichnet Kursanstieg Palatin Technologies, Inc. (NYSE American:... ► Artikel lesen | |
BIOXXMED | 0,320 | -46,67 % | XETR DELETION OF INSTRUMENTS FROM XETRA - 31.03.2025 | The following instruments on Xetra do have their last trading day on 31.03.2025.Die folgenden Instrumente auf Xetra haben ihren letzten Handelstag am 31.03.2025.ISIN NameDE000A4BGGE4 bioXXmed AG ► Artikel lesen | |
ORGANOVO | 2,650 | 0,00 % | Organovo, Inc.: Organovo Provides Business Update | SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) ("Organovo" or the "Company"), a clinical stage biotechnology company focused on developing novel treatment approaches... ► Artikel lesen | |
OCUGEN | 0,610 | -6,73 % | Ocugen: Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200-a Novel Fusion Protein for Diabetic Macular Edema | OCU200 has a very favorable safety and tolerability profileNo serious adverse events related to the study drug have been reportedDosing of the second cohort has been approved MALVERN, Pa., March 18... ► Artikel lesen | |
SIRONA BIOCHEM | 0,037 | -100,00 % | XFRA ZSB: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILSIRONA BIOCHEM CORP.... ► Artikel lesen | |
BIO-GATE | 0,765 | +5,52 % | Bio-Gate: Vielversprechende Wachstumschancen | Nach Darstellung der Analysten Matthias Greiffenberger und Cosmin Filker von GBC hat die Bio-Gate AG im Geschäftsjahr 2024 (per 31.12.) einen leichten Umsatzrückgang verbucht, besitzt aufgrund der innovativen... ► Artikel lesen | |
DEFENCE THERAPEUTICS | 0,722 | +4,64 % | Kursraketen und Übernahmefantasie! Steyr Motors, Evotec und Defence Therapeutics! | Steyr Motors reitet jetzt nicht nur die Rüstungs-, sondern auch die Übernahmewelle. Nach der Kooperationsmeldung mit einer Rheinmetall-Tochter ist der Nischenwert zum Shootingstar geworden. Allerdings... ► Artikel lesen | |
VAXART | 0,369 | -5,04 % | Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SOUTH SAN FRANCISCO, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the "Company" or "Vaxart") today announced that on March 24, 2025, the independent members of the Board... ► Artikel lesen | |
CELLECTAR BIOSCIENCES | 0,280 | -5,41 % | Cellectar Biosciences: Multibagger mit Ansage? | Cellectar Biosciences (WKN: A3DQSD) heißt unsere Top-Spekulation der Stunde. Das auf Radiopharmaka gegen Krebs spezialisierte Biotechunternehmen konnte gestern eine wichtige Einigung mit der US-Gesundheitsbehörde... ► Artikel lesen | |
BURCON NUTRASCIENCE | 0,057 | -4,03 % | Burcon NutraScience Corporation: Burcon Integrates Protein Technologies at Galesburg Facility | Vancouver, British Columbia--(Newsfile Corp. - April 1, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in the development of... ► Artikel lesen | |
AFFIMED | 0,930 | -100,00 % | Affimed N.V.: Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting | MANNHEIM, Germany, March 25, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,... ► Artikel lesen | |
IMMUNIC | 1,018 | +0,99 % | EQS-News: Immunic AG: Immunic, Inc. to Participate in Scientific and Industry Conferences in April | Issuer: Immunic AG
/ Key word(s): Conference
Immunic, Inc. to Participate in Scientific and Industry Conferences in April
01.04.2025 / 12:30 CET/CEST
The issuer is solely... ► Artikel lesen | |
AIM IMMUNOTECH | 0,116 | +0,87 % | AIM ImmunoTech Inc.: AIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update | Continued execution across Ampligen® (rintatolimod) clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer space Expected milestones over... ► Artikel lesen | |
T2 BIOSYSTEMS | 0,082 | -4,66 % | T2 Biosystems, Inc. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | ||
CEL-SCI | 0,215 | +1,23 % | CEL-SCI Aktie: Rückenwind an der Börse! | Das Biotechnologieunternehmen sichert sich 2,56 Millionen Dollar für Krebsimmuntherapie Multikine und erhält positive Signale der FDA zum statistischen Analyseplan. Die CEL-SCI Corporation, ein Biotechnologieunternehmen... ► Artikel lesen |